Natural Products Originating From *Tripterygium wilfordii* Hook F Exhibit Distinct Pharmacological Activities
=============================================================================================================

*Tripterygium wilfordii* Hook F (TWHF), also known as Lei Gong Teng (Thunder God Vine), has a long history of improving symptoms of RA ([@B99], [@B99]; [@B7]; [@B64]). The root bark of TWHF exhibits pharmacological activities against inflammation ([@B81]; [@B130]), autoimmune disorders ([@B15]), fibrosis, atherosclerosis, neurodegeneration ([@B16]), and kidney diseases ([@B113]). TWHF extracts are used for treating autoimmune and inflammatory diseases in clinical practice ([@B92]). In China, the Lei Gong Teng tablet and Lei Gong Teng multiglycoside tablet have been developed for RA treatment since the 1970s ([@B108]). The chloroform/methanol extract of TWHF attenuates inflammation in patients with Crohn's disease by inducing the differentiation of Foxp3^+^ T regulatory (Treg) cells and suppressing the serum levels of pro-inflammation cytokines, such as interleukin-10 and TGF-β ([@B71]).

Several classes of bioactive substances have been isolated and characterized from TWHF, including sesquiterpenes, diterpenes (triptolide, tripdiolide, and triptonide), triterpenes (celastrol, pristimerin, and wilforlide A), lignans, glycosides, and alkaloids ([@B7]; [@B70]; [@B114]). Triptolide and celastrol are considered as the most active and promising components of TWHF. Thus, their pharmacological activities and mechanisms of action have been extensively investigated in many disease models (**Table [1](#T1){ref-type="table"}**).

###### 

Pharmacological activities of triptolide and celastrol *in vivo*.

  Disease model                  Natural product   Animal model                                                                        Experimental detail                                                Outcome of the study                                                                    Reference
  ------------------------------ ----------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------- -----------------
  RA                             Triptolide        Bovine type II collagen-induced RA in male SD rats                                  30 μg/kg (*s.c.*) for 32 days                                      Downregulation of RANKL-mediated ERK/AKT signaling pathway                              [@B31]
                                 Celastrol         Freund's complete adjuvant-induced RA in C57BL/6 mice                               0.5 mg/kg/day (*i.p.*) for 40 days                                 Suppression the inflammatory activities of neutrophils                                  [@B9]; [@B138]
  Acute promyelocytic leukemia   Triptolide        HL-60 cell implanted xenograft in female NOD/SCID mice                              2 or 4 mg/kg (*i.p.*) for 21 days                                  Activatation of mitogen-activated protein kinase kinase-3/p38 signaling pathway         [@B97]
                                 Celastrol         HL-60 cell implanted xenograft in nude mice                                         2 mg/kg/day (*i.g.*) for 21 days                                   Mitochondrial-initiated apoptosis                                                       [@B144]
  Colitis                        Triptolide        IL-10^-/-^ mice                                                                     0.07 mg/kg/other day (*i.p.*) for 8 weeks                          Suppression of IL-6/STAT3/SOCS3 signaling pathway                                       [@B74]
                                 Celastrol         IL-10^-/-^ mice                                                                     2 mg/kg (*i.g.*) for 7 days                                        Induction of autophage                                                                  [@B147]
                                 Celastrol         DSS-induced colitis in C57BL/6J mice                                                1 mg/kg (*i.g.*) for 7 days                                        Apoptotic cell death                                                                    [@B51]
                                 Celastrol         Caspase 1^-/-^ mice                                                                 1 mg/kg (*i.g.*) for 7 days                                        Inhibiting activation of NLRP3 inflammasommes                                           [@B136]
  Hepatocellular carcinoma       Triptolide        Huh-7 xenograft in nude mice                                                        Minnelide (prodrug of triptolide) 0.21 mg/kg (*i.p.*) for 7 days   Inhibiting NF-κB activity                                                               [@B3]
                                 Celastrol         DEN-induced HCC in rat                                                              2, 4, and 8 mg/kg/day (*i.g.*) for 20 weeks                        Induction of apoptotic cell death                                                       [@B10]
  Gastric cancer                 Triptolide        SC-M1 cell xenograft in SCID mice                                                   0.4 mg/kg (*i.v.*) for 3 weeks                                     Induction of apoptotic cell death                                                       [@B69]
                                 Celastrol         AGS cell xenograft in mice                                                          1--2 mg/kg/day (*i.g.*) for 12 days                                Induction of apoptotic cell death                                                       [@B65]
  Osteosarcoma                   Triptolide        SAOS2 or U2OS cell xenograft in nude mice                                           150 nM for 1 to 5 weeks                                            Induction of apoptotic cell death                                                       [@B104]; [@B52]
                                 Celastrol         HOS cell xenograft in nude mice                                                     1--2 mg/kg/day (*i.p.*) for 7 days                                 Apoptotic cell death                                                                    [@B72]
  Melanoma                       Triptolide        B16-F10 cell xenograft in C57BL/6J mice                                             0.15--0.3 mg/kg daily (*i.g.*) for 14 days                         Regulation of inflammatory T cell number and expression of pro-inflammatory cytokines   [@B78]
                                 Celastrol         B16 cell xenograft in C57BL/6J mice                                                 1--3 mg/kg (*i.g.*) once a day for 20 days                         Inhibition the PI3K/Akt/mTOR signaling pathway                                          [@B66]
  Pancreatic cancer              Triptolide        SW1990 cell xenograft in BALB/c/nu/nu                                               0.2--0.4 mg/kg (*i.p.*) for 3 weeks                                Supression of HIF-1α through c-MYC-dependent mechanism                                  [@B22]
                                 Celastrol         PANC-1 cell xenograft in nu/nu athymic female mice                                  3 mg/kg (*i.p.*) for 70 days                                       Disturbing HSP90-CDC37 interaction                                                      [@B143]
  Mesothelioma                   Triptolide        H2373 or H513 cell xenograft in BALB/c/nu mice                                      0.42 mg/kg (prodrug of Triptolide, *i.p.*) for 28 days             Suppression of HSP70 expression                                                         [@B50]
  Colon cancer                   Triptolide        Genotoxic colonic carcinogen- and DSS- induced model in male Crj: CD-1 (ICR) mice   0.1--1 mg/kg (*i.g.*) for 20 weeks                                 Reducing inflammation, restrict tumor formation and growth                              [@B121]
                                 Celastrol         Azoxymethane (AOM) and DSS induced colon cancer in C57BL/6J mice                    2 mg/kg/day by gavage for 14 weeks                                 Suppressing inflammatory response and epithelial--mesenchymal transition                [@B76]
  Lung cancer                    Triptolide        Orthotopic lung cancer model in nude rats                                           400 μg/kg intranasal instillation for 8 weeks                      Targeting the HA-CD44/RHAMM signaling axis                                              [@B105]
                                 Celastrol         A549 or H1975 cell xenograft in Balb/c nude mice                                    1 or 3 mg/kg/days, or 5 mg/kg, twice/week (*i.p.*) for 3 weeks     Inhibiting CIP2A-Akt pathway                                                            [@B83]
  Neuroinflammation              Triptolide        Middle cerebral artery occlusion in male SD rats                                    0.2 mg/kg (*i.p.*) at the beginning for 24 h                       Inhibition of NF-κB activity                                                            [@B6]
                                 Celastrol         Optic nerve crush (ONC) in adult Brown Norway rats                                  1--5 mg/kg (*i.p.*) for 2 weeks                                    Activation of TNF-α-mediated cell death                                                 [@B63]
  Diabetes                       Triptolide        High-fat and high-sucrose diet-induced diabetes in Wistar rats                      100 μg/kg (*i.g.*) for 8 weeks                                     Inhibiting inflammation and macrophage infiltration                                     [@B89]
                                 Celastrol         High energy diet and streptozotocin-induced diabetes in male SD rats                1--6 mg/kg (*i.p.*) for 8 weeks                                    Anti-oxidant activity                                                                   [@B34]
  Obesity                        Triptolide        Ob/Ob diabetic mice with diabetic nephropathy                                       25 and 50 μg/kg day for up to 12 weeks                             Attenuating albuminuria and renal lesion accompanied with dyslipidaemia and obesity     [@B30]
                                 Celastrol         High fat diet-induced obesity in C57BL/6J mice                                      1--3 mg/kg (*i.g.*) for 2--8 weeks                                 Increasing sensitivity to leptin through activtion transcription of HSF1-PGC1α          [@B90]
                                 Celastrol         Nur77^-/-^ mice injected with LPS+GalN                                              0.2 or 0.5 mg/kg (*i.p.*) once 12 h before LPS injection           Promoting nuclear receptor 77 translocation from nucleus to mitochondria                [@B41]
                                 Celastrol         Ob/Ob mice                                                                          100 μg/kg (*i.p.*) for 11 days                                     Increasing leptin sensitivity                                                           [@B79]
  Renal damage                   Triptolide        Renal ischemia in SD rats                                                           4.17 μmol/day (*i.v.*) for 3 days before renal surgery             Inhibiting proinflammatory cytokines and chemotactic cytokines expression               [@B29]
                                 Celastrol         Renal ischemia in rat                                                               4--6 mg/kg (*i.p.*) once 30 min before renal ischemia              Inhibiting NF-κB activation and inflammation                                            [@B18]
  Cardiovascular disease         Triptolide        Ischemia--reperfusion surgery in Wistar rats                                        25, 50, and 100 μg/kg 1 h before surgery                           Activation of nuclear factor 2/heme oxygenase 1 signaling pathway                       [@B135]
                                 Celastrol         High-fat/high-cholesterol diet model in apoE^-/-^ mice                              1--2 mg/kg (*i.p.*) for 4 weeks                                    Inhibiting lectin-like oxidized low density lipprotein                                  [@B33]
  Lung inflammation              Celastrol         Intranasal administration of LPS in male Babl/c mice                                1--50 μg/kg (*i.v.*) at the beginning for 12 h                     Inhibiting NF-κB signaling pathway                                                      [@B118]
                                 Celastrol         NB4 cells-model of differential syndrome in male NOD/SCID mice                      300 μg/ml (*i.p.*) for 6 days                                      Reducing cytokimes, chemokines, and adhesive molecule expression                        [@B127]

Pharmacological Activities of Triptolide
========================================

Triptolide, a diterpenoid triepoxide, was first isolated and characterized from TWHF in [@B62]. Subsequent studies revealed that triptolide exhibit potent pharmacological activities against inflammation, fibrosis, cancer, viral infection, oxidative stress, and osteoporosis ([@B19]; [@B36]; [@B85]). Results from molecular docking and dynamics simulation study suggest that triptolide has similar structures as hormones and thus can also bind to nuclear receptors ([@B80]). Triptolide selectively inhibits the chaperone activity of peroxiredoxin I, an antioxidant enzyme and molecular chaperone that plays essential functions in the development of cancer and inflammation ([@B148]). The XBP1 subunit of the transcription factor TFIIH core complex is identified as one of the molecular targets of triptolide, which was critical for the inhibitory activity of triptolide to RNA polymerase II-mediated transcription ([@B109]). This unique feature is the reason that triptolide is active to most type of diseases in preclinical investigation, such as inflammation and cancer ([@B38]; [@B133]).

Anti-inflammation Activities of Triptolide
------------------------------------------

Triptolide exhibits anti-inflammation activity in T helper cell-mediated immunity especially against RA and inflammatory bowel diseases. It primarily attenuates inflammatory response in RA by inhibiting NF-κB, NF-κB/TNF-α/vascular cell adhesion molecule-1, and TGF-β1/α-smooth muscle/vimentin signaling pathways induced by TNFs and TLR4 ([@B43]; [@B31]). In RA, triptolide down-regulates the expression levels of myeloid cells-1 and DNAX-associated protein 12 ([@B23]). In IL-10 deficient mice colitis model, triptolide ameliorates post-surgical intestine inflammation by suppressing the miRNA-155/inositol polyphosphate-5-phosphatease D signaling pathway and producing of inflammatory cytokines ([@B125]). Triptolide also suppresses IL-6/signal transducers, the activators of transcription (STAT)3/suppressor of the cytokine signaling (SOCS)3 signaling pathway, and promotes apoptotic cell death of lamina propria mononuclear cells ([@B74]).

Triptolide suppresses abnormally activated innate immune response and attenuates LPS-induced acute lung injury by decreasing leukocyte numbers, myeloperoxidase activity, and secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 ([@B118]). The suppression of prostaglandin E2 receptor 2 signaling pathway leads to the inhibitory activity of triptolide on LPS-induced inflammation and expression of inducible nitric oxide synthase in microglia ([@B142]). Treatment with triptolide prevents kidney damage by reducing the expression level of malondialdehyde and increasing superoxide dismutase activity by modulating the NF-κB signaling pathway in rats ([@B154]). The formation of the NLRP3 inflammasomes is abrogated by triptolide in transverse aortic constriction in mice ([@B73]). Triptolide diminishes neuroinflammation through the downregulation of p38 MAPK and NF-κB signaling pathways in rat models of depression or middle cerebral artery occlusion, respectively ([@B112]; [@B128]; [@B6]; [@B140]; [@B40]; [@B42]).

Anticancer Activities of Triptolide
-----------------------------------

Triptolide suppresses the proliferation and promotes apoptotic cell death in various cancers, especially hard-to-treat types, including prostate and pancreatic cancers. Prostate and pancreatic cancers are the third and fourth leading causes of cancer death in western countries, respectively ([@B49]). Treatment with triptolide induces the nuclear accumulation of p53 and apoptotic cell death in primary cultures of human prostatic epithelial cells ([@B60]). The growth of prostate cancer xenograft in nude mice is inhibited after triptolide decreases the expression levels of SUMO-specific protease 1 and androgen receptor ([@B45]). Furthermore, the sensitivity of gemcitabine-resistant pancreatic cancer cells to cisplatin treatment is enhanced by triptolide through activation of mitochondria-initiated cell death pathway and suppression of HSP27 expression ([@B156]).

The generally recognized molecular target of triptolide is the XBP1 subunit of transcription factor TFIIH ([@B109]). Triptolide covalently binds to the Cys342 of XBP1 by the 12,13-epoxide group ([@B39]), and thus inhibits transcription and nucleotide excision repair activity of RNA polymerase II in an ATP-dependent manner ([@B96]; [@B109]). In addition, triptolide induces phosphorylation of RPB1 subunit of RNA polymerase II on Ser1878 by activating cyclin-dependent kinase (CDK)7, which promotes degradation of RPB1 and subsequently induced cancer cell death ([@B91]).

Developing MDR is one of the biggest challenges for cancer therapy ([@B56]). Triptolide suppresses the expression of MDR protein, and induces apoptotic cell death of drug-sensitive parental KB cells and multidrug-resistant KB-7D and KB-tax cells ([@B14]). The inhibitory activity on MDR cell lines is mediated through the suppression of overall transcription mediated by RNA polymerase II in a CDK7-dependent manner. In addition, triptolide alters the activity of *p*-glycoprotein drug efflux and mRNA level of MDR genes ([@B133]).

Pharmacological Activities of Celastrol
=======================================

Pharmacological Activities of Celastrol Mediated through HSP90
--------------------------------------------------------------

Celastrol was first reported to inhibit HSP90 by promoting the nuclear translocation of HSF1, a transcription factor regulating HSP genes by binding to the heat shock elements in yeast and mammalian cells ([@B110]; [@B2]; [@B21]). Thus celastrol was defined as a HSP90 inhibitor.

Classical HSP90 inhibitors suppress the ATPase activity of HSP90 ([@B26]). Celastrol induces the degradation of HSP90 and its client proteins without interfering the bonds between ATP and HSP90 in pancreatic cancers and NSCLC in micromolar concentration ([@B143]; [@B24]). Treatment with celastrol also induces the dephosphorylation and degradation of HSP90/CDC37 client protein kinases, including Raf family proteins, AKT, MEK1/2, CDK4, and epidermal growth factor receptor (EGFR) in HCC cells, leading to the inhibition of proliferation and induction of apoptotic cell death ([@B122]). Suppressing the expression of HSP90 by celastrol also sensitizes glioblastoma cells to celastrol treatment ([@B8]).

HSP90 activity can be modulated through celastrol treatment. Celastrol restores the disrupted association between HSP90 and its co-chaperone CDC37/HSP90-HSP70 complex, and thus reduces HSP90-mediated degradation of glucocerebrosidase (GCase) ([@B132]; [@B111]). The resulting increased quantity and catalytic activity of GCase compensates for glucosidase mutation, which is the primary cause of Gaucher disease ([@B47]; [@B132]). Treatment with celastrol also induces expression of HSP72, phosphorylation, and nucleus accumulation of HSF1, which abrogates proteasome activity in dexamethasone-induced atrophy ([@B37]).

Anticancer Activities of Celastrol Independent of HSP90
-------------------------------------------------------

Celastrol effectively inhibits the growth of melanoma xenograft in mouse by triggering ROS-mediated caspase-dependent and caspase-independent apoptotic cell death, and inactivating the PI3K/AKT signaling pathway with the dosage of 1 mg/kg ([@B66]). Treatment with celastrol also suppresses the proliferation of osteosarcoma and bladder cancer cells via ROS/c-JNK and mitochondrial apoptotic pathways, and induces apoptosis and autophagy both *in vivo* and *in vitro* ([@B72]; [@B137]).

Celastrol treatment initiates programmed cell death by activating glycogen synthase kinase-3β ([@B25]). The treatment induces cell cycle arrest, activation of caspase 3/7, and apoptosis in c-Met-deficient Huh7 cells, Bel 7402 cells, and diethylnitrosamine-induced liver cancer in rats ([@B10]). It inhibits the viability of HepG2 cells by suppressing the TLR4-NF-κB signaling pathway when used alone ([@B103]), and suppresses EGFR expression when combined with lapatinib ([@B131]). Celastrol also inhibits cancer growth by activating TNF-α-induced NF-κB signaling pathway ([@B57]), inhibiting the mTOR/ribosomal protein S6 kinase/eIF4E/AKT and ERK signaling pathway, and down-regulating hypoxia-inducible factor-1α (HIF-1α) ([@B88]). Celastrol inhibits the growth of MCF-7 breast cancer cells through AMPK ([@B59]), and induces apoptosis in HT-29 colon adenocarcinoma cells through the canonical WNT/β-catenin pathway ([@B86]). Furthermore, celastrol suppresses the proliferation and invasion of ulcerative colitis-related colorectal cancer and NSCLC by inhibiting epithelial--mesenchymal transition, increasing E-cadherin expression, down-regulating N-cadherin, vimentin, and snail ([@B76]; [@B84]).

Treatment with celastrol inhibits the proliferation, migration, and invasion of chondrosarcomas cells by suppressing the inhibitor of the protein phosphatase 2A-Akt signaling pathway *in vivo* ([@B83]). Celastrol rapidly reduces the expression level of c-MYC protein and stimulates an energy crisis by depleting ATP, inducing accumulation of neutral lipid, and activating AMPK, thereby ultimately induces cell cycle arrest and apoptotic cell death in human cancer cells ([@B115]). In addition, celastrol inhibits the growth of head and neck cancer cells by activating C/EBP-homologous protein and XBP1s, which increase the transcription of ER stress target genes and subsequently induces ER stress ([@B28]).

Anti-inflammation Activities of Celastrol Independent of HSP90
--------------------------------------------------------------

Treatment with celastrol reduces inflammation in several disease models independent of HSP90. Celastrol significantly suppresses inflammation by reducing the secretion of IL-1β and IL-18, and inactivating the NLRP3 inflammasomes and caspase-1 in LPS/ATP-primed macrophage cells ([@B126]; [@B136]). Celastrol ameliorates colitis in IL-10-deficient mice by reducing colon myeloperoxidase concentration and inhibiting colonic pro-inflammatory cytokines via PI3K/Akt/mTOR signaling pathway ([@B147]). It also ameliorates dextran sulfate sodium-induced colitis in caspase-1^-/-^ mice by inhibiting the activation of NLRP3 inflammasomes and the subsequent secretion of IL-1β ([@B136]). Celastrol potentiates mitochondrial damage and inflammation in palmitate-induced insulin resistance in C3A hepatocytes ([@B1]). Treatment with celastrol also inhibits acute liver inflammation through the Nur77-dependent pathway and activation of autophagy in LPS and [D]{.smallcaps}-galactosamine-induced inflammation in mice ([@B32]). Although it inhibits the differentiation of Th17 cells, celastrol enhances the production of Treg cells by restricting the activation of STAT3 and its downstream target genes. In adjuvant arthritis rats, these processes suppress joint inflammation ([@B5]).

Activities of Celastrol in Metabolic Diseases
---------------------------------------------

Metabolic diseases are often associated with over-activated inflammatory response, for example obesity and diabetes ([@B106]). Delaminating pathogenic factors of the disease progression lead to reduced inflammation. Celastrol inhibits obesity and metabolic dysfunction by increasing energy expenditure, activation of brown adipose tissue, and expression of mitochondrial genes *in vivo*. Treatment with celastrol activates the transcription of HSF1 and expression of peroxisome proliferative activated receptor coactivator-1α in mouse adipose tissues and muscle ([@B90]), promoting thermogenesis and the remodeling of white adipose tissues. In addition, celastrol inhibits high fat diet-induced obesity in Nur77^-/-^ mice by activating autophagy and promoting the interaction between Nur77 and TRAF2 ([@B41]). Celastrol treatment reduces body weight gain and food intake in both high fat-fed obese in diabetes (db/db) and leptin-deficient (ob/ob) mice by potentiating STAT3-dependent leptin signaling and inhibiting ER stress ([@B79]).

Translational Development of Triptolide and Celastrol
=====================================================

Despite the various activities offered, clinical application of triptolide and celastrol remains limited due to their narrow therapeutic window and poor solubility ([@B119]). The major toxicity of triptolide includes hepatic and cardiac toxicity. Triptolide induces hepatotoxicity by suppressing the transcription of four major cytochromes P450 (CYP) isoforms, namely CYP3A, CYP2C9, CYP2C19, and CYP2E1, thus decreasing the substrate affinities and activities of these CYP enzymes, which are vital to normal metabolism regulation ([@B87]). Decrease in CYP enzymes antagonizes the activity of other drugs metabolized through these CYP isoforms ([@B87]). Treatment with triptolide leads to cardiac cytotoxicity through induction of oxidative stress, mitochondrial dysfunction, and apoptotic damage regulated by the mitochondria-mediated apoptotic signaling pathway in cardiomyocytes ([@B151]). Considerable effort has been exerted for the reduction of toxicity of triptolide and celastrol, including combination therapy, nanoparticle coating for enhancement of water solubility and targeted delivery, and development of water-soluble analogs of triptolide and celastrol. The structural basis of the toxicity of TWHF compounds can be determined through in-depth understanding of the relationship between structures and activities of their functional analogs.

Combination Treatment for Toxicity Reduction
--------------------------------------------

Lowering the dosage used of TWHF compounds by combining them with agent(s) effectively reduces their cytotoxicity and related adverse effects. Combination treatment offer new opportunities for the translational development of triptolide and celastrol. Active components from the same herb can synergize with other compounds isolated from the same herb ([@B153]). For example, combination treatment of triptolide and celastrol synergistically inhibits cell growth, induces cell cycle arrest at G2/M phase and apoptosis, and increases intracellular ROS accumulation in many types of cancer cells, including H1299 and H157 lung cancer cells ([@B54]).

Triptolide has been used for the reduction of resistance against chemotherapeutic agents. Low doses of triptolide reverses resistance to cytarabine and doxorubicin in acute lymphoblastic leukemia cell line NALM-6/R and primary cells isolated from patients with relapsed or refractory acute lymphoblastic leukemia in the mouse xenograft model ([@B145]). The combination treatment of triptolide and oxaliplatin significantly inhibits the proliferation of colon cancer cell lines by regulating the Wnt/β-catenin pathway in nanomolar concentration ([@B82]). Triptolide together with hydroxycamptothecin exhibits broad-spectrum anticancer activities by regulating MAPK and Akt signaling pathways ([@B93]). Combination treatment with farnesoid X receptor activator GW4064 relieves triptolide-induced hepatic toxicity ([@B55]). The treatment reduces incidence of spontaneous lung cancer from 70 to 10% by potentiating the NF-κB signaling pathway-mediated production of proinflammatory cytokines *in vivo* when used in a low dose (1 mg/kg body weight) and in combination with aspirin ([@B150]).

The combined treatment of celastrol and histone deacetylases inhibitor suberoylanilide hydroxamic acid simultaneously activate the NF-κB and E-cadherin signaling pathway, thus substantially inhibit growth of human cancer cells *in vitro* and *in vivo* ([@B149]). When combined with ABT-737, a BH3 mimetic inhibitor of Bcl-xL, Bcl-2, and Bcl-w, celastrol synergistically suppresses the proliferation of HCC cells and induces apoptotic cell death ([@B155]). The combination treatment with triptolide and celastrol exhibits synergistic anticancer activity in H1299 human NSCLC cells and H157 human oral carcinoma xenografts by inhibiting HSP90 activity and reducing ROS level ([@B54]).

Nanoparticle Coating to Enhance Solubility and Organ Targeting
--------------------------------------------------------------

Nanoparticle is used as drug delivery system to improve therapeutic efficacy by increasing solubility and organ targeting through electrostatic interactions or receptor and/or membrane binding ([@B152]).

Follicle-stimulating hormone (FSH)-β-peptide modified nanoparticle is used to increase water solubility and reduce cytotoxicity of triptolide in ovarian cancer mouse model ([@B12]). Administration of FSH-β-peptide nanoparticle containing triptolide suppresses the serum level of antimullerian hormone, reduces prominent ovarian fibrosis, vacuolar changes, and follicle numbers ([@B12]). A nanoparticle formed with PF-A299-585 (amino acid 299--585) peptide fragment of human serum albumin increases the kidney targeting property of triptolide, and exhibits comparable anti-inflammatory activity with less cytotoxicity in LPS-stimulated Madin-Darby canine kidney cells and in membranous nephropathic rodent model ([@B139]). Triptolide packed with the reduction-sensitive lipid-polymer hybrid nanoparticles inhibits proliferation of human oral cavity squamous cell carcinoma cells more effectively with a low combination index with doxorubicin and reduced cytotoxicity ([@B124]). Coating with pH-sensitive floating nanoparticles allows specific uptake of triptolide by liver cancer cells, results in improved efficacy as well as reduced cytotoxicity compared with triptolide alone *in vivo* and *in vitro* ([@B77]). Disodium phosphonooxymethyl nanoparticle extends the shelf life of triptolide, reduces the dosage required to inhibit growth of human ovarian cancer xenograft compared with that of triptolide ([@B98]).

PEGylated distearoyl phosphatidylcholine liposomes packed with celastrol exhibits higher efficiency in inducing apoptotic cell death in prostate cancer cells, compared with celastrol dissolved in dimethyl sulfoxide ([@B123]). This formula prolongs the blood circulation time of celastrol, increasing bioavailability and reducing the frequency of dosing ([@B123]). Celastrol nanoparticles significantly inhibits suture-induced corneal neovascularization by reducing macrophage infiltration and decreasing the expression of vascular endothelial growth factor and matrix metalloproteinase 9 in rat cornea ([@B75]; [@B101]). Mesoporous silica nanoparticle and axitinib in PEGylate lipid bilayers increases the inhibitory activity of celastrol on angiogenesis and mitochondrial function, and enhances its anticancer activity in SCC-7, BT-474, and SH-SY5Y cells ([@B17]). Glucose-functionalized mesoporous silica nanoparticles significantly enhances tissue targeting and inhibitory activity of celastrol toward Hela and A549 cancer cells ([@B94]). Celastrol-albumin nanoparticles exhibits tissue targeting property to mesangial cells, and attenuates proteinuria, inflammation, and glomerular hypercellularity in mesangial cell-mediated glomerulonephritis ([@B35]). Celastrol-albumin nanoparticles reduces the accumulation of free celastrol in off-target organs and tissues, thus successfully reducing the systemic toxicity of celastrol ([@B35]).

Development of Water-Soluble Analogs of Triptolide and Celastrol
----------------------------------------------------------------

Several water-soluble analogs of triptolide and celastrol were synthesized and evaluated in laboratory animal models and clinical trials. PG490-88, as a water-soluble succinate salt analog of triptolide, more specifically and effectively blocks pulmonary fibrosis in intratracheal bleomycin mouse model than triptolide ([@B61]). PG490-88 also inhibits the growth of cancer-derived primary cultures of human prostatic epithelial cells in a p53-dependent manner ([@B60]). MRx 102, a triptolide derivative with C-14-hydroxyl modification of amine ester group, differentially regulates the expression of retinoid X receptor-α (RXRα) but not the level of full length of RXRα, and inhibits cancer cell growth through the inhibition of AKT signaling pathway ([@B117]).

(5*R*)-5-hydroxytriptolide (LLDT-8) is a triptolide analog with a favorable safety profile, the efficacy of which will be examined for the treatment of RA and cancer in phase II clinical trials ([@B116]; [@B100]). LLDT-8 maintains the immune suppressive activity of triptolide ([@B141]). Treatment with LLDT-8 ameliorates anti-GBM glomerulonephritis by regulating the Fcγ receptor signaling ([@B100]). LLDT-8 exhibits anti-inflammation activity and inhibits transcription in a similar fashion as triptolide ([@B13]). However, testis toxicity is associated with long-term LLDT-8 treatment due to its upregulation of TGF-β activated kinase 1 ([@B134]).

Minnelide, a phosphonooxymethytriptolide disodium salt, was synthesized by reacting triptolide with acetic anhydride in dimethyl sulfoxide at room temperature for 5 days ([@B19]). Minnelide inhibits the growth of multiple cancers in pre-clinical studies ([@B19]; [@B50]; [@B95]; [@B4]; [@B48]), for example, colon cancer and metastasis to liver ([@B95]). The growth of pancreatic cancer in KRas and TP53 mutant mouse model (KRas^G12D^; Trp53^R172H^; Pdx-1Cre) is also attenuated by minnelide ([@B19]). No overt signs of toxicity is observed during more than 1 year's treatment of minnelide in athymic nude mice bearing human pancreatic cancer xenograft ([@B19]); thus the therapeutic window of minnelide is greatly enhanced than that of triptolide. The efficacy of minnelide in patients with refractory pancreatic cancer is currently evaluated in phase II clinical trial (NCT03117920).

Few C6-indole modified water soluble analogs of celastrol were synthesized. NST001A, a sodium salt of celastrol, inhibits the growth of human colon cancer cell-Colo 205 colon cells *in vitro* and *in vivo* ([@B107]). Two celastrol derivatives (NST001 and NST001B) also exhibits enhanced potency against the growth of HCC cells than celastrol ([@B107]). CEL20 disrupts the interaction of HSP90-CDC37 more efficiently than celastrol in A549, MCF7, and pancreatic Panc-1 human cancer cell lines ([@B53]).

Structure-Activity-Relationship of Compounds Isolated from TWHF
---------------------------------------------------------------

The structural-activity-relationship of major compounds isolated from TWHF against key signaling pathways regulating inflammation have been studied by many groups, aiming to evaluate SAR for the future modifications of TWHF compounds.

*Tripterygium wilfordii* Hook F compounds including triptolide with epoxide are attacked by a well-positioned -SH, which is one of the determinant factors for their pharmacological activities ([@B39]). Triptolide binds to the cysteine residues of target proteins through covalent bond; and thus modifies the properties and activities of the target proteins. However, no epoxide moiety is observed on other TWHF compounds such as withaferin A and celastrol, although they exhibits the same activities as triptolide ([@B148]). In withaferin A and celastrol, 1,4-dipolar structure constructed by the carbonyl and adjacent double carbon-carbon bond that binds to the cysteine residues of the target proteins. The epoxide and 1,4-dipolar structure are both electrophilic groups that can be attacked by -SH via ring-opening and Michael reactions, respectively. Therefore, the covalent bond between the electrophilic structure of TWHF compounds and cysteine residues on target proteins could be considered as determinant factor for the SAR of TWHF compounds.

The difference in the Michael addition and ring-opening reactions of celastrol, pristimerin, and triptolide may have led to the huge difference among the biological activities of these TWHF compounds. TWHF compounds with the electrophilic structure, including triptolide, celastrol, and pristimerin exhibit similar inhibitory activities against NF-κB, STAT3, and SMAD2/3 signaling pathways (**Table [2](#T2){ref-type="table"}**). Comparatively, the potency of celastrol and pristimerin against key signaling pathways regulating inflammation is lower than that of triptolide (**Table [2](#T2){ref-type="table"}**). Especially that the concentration of pristimerin required to suppresses NF-κB activation already reduces cell viability, suggesting that the immune suppressive activity of pristimerin is due to the inhibition of cell growth. This is in line with other reports that pristimerin minimally inhibits the proliferation of cancer cells ([@B44]; [@B146]).

###### 

Activities of major compounds isolated from THWF on different signaling pathways.

  Nature product   Activity (EC~50~^a^, detection method)                                                   Cell type and viability at EC~50~ (detection method)                      Reference
  ---------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------
  Triptolide       Inhibit TRAIL-induced NF-κB at 20 ng/ml (reporter assay)                                 Lung cancer A549 and NCI-H1299 cell lines, 75--90% (MTT assay)            [@B67], [@B68]
  Triptolide       Inhibit IL-6-stimulated STAT3 at 30 nM (reporter assay)                                  Colon cancer cell line SW480 cells, 10% (MTT assay)                       [@B121]
  Triptolide       Inhibit TGF-β1-activated SMAD2/3 at 10 nM (Western blot analysis)                        Airway smooth muscle cells, 70% (MTT assay)                               [@B11]
  Celastrol        Inhibit TGF-β1-stimulated NF-κB at 1000 nM (Western blot analysis)                       Squamous cell carcinoma 228 cell, 90% (MTT assay)                         [@B27]
  Celastrol        Inhibit TNF-α-stimulated NF-κB at 3000 nM (reporter assay)                               Human embryonic kidney subclone A293 cells, 80% (MTT assay)               [@B102]
  Celastrol        Inhibit IL-6-stimulated STAT3 at 1000 nM (Western blot analysis)                         Multiple myeloma U266 cells, 90% (MTT assay)                              [@B58]
  Pristimerin      Inhibit NF-κB p65/DNA binding activity at 300--400 nM (ELISA assay)                      BXPC-3, PNCA-1, and AsPC-1 pancreatic cancer cells, 50% (cell counting)   [@B120]
  Pristimerin      Inhibit NF-κB p65 protein expression at 600 nM (Western blot analysis)                   PNCA-1 cells, 25% (MTS assay)                                             [@B20]
  Pristimerin      Inhibit LPS-stimulated NF-κB activation through TLR4 at 500 nM (p65/DNA binding assay)   Cellosaurus BV2 cells, 100% (MTT assay)                                   [@B46]

a

50% inhibition of efficacy to signaling pathway to untreated control.

Inspired by the epoxide's effect on protein proposed by [@B148], the epoxide moieties on the C-6a and C-7a positions of triptolide could act as acceptors for cysteine (**Figure [1](#F1){ref-type="fig"}**). Triptolide directly binds to cysteine via the ring-opening interaction between epoxide and -SH moiety of cysteine, which could lead to the dissociation of these proteins to their downstream target elements. Instead of epoxide, the 1,4-dipolar structure constructed by the carbonyl on C-2 and its adjacent alkenyl on celastrol and pristimerin acts as an acceptor of cysteine (**Figure [1](#F1){ref-type="fig"}**). This structure can combine with -SH by the Michael reaction. The activities of the Michael addition and ring-opening reaction might have caused the differences among the pharmacological activities of celastrol, pristimerin, and triptolide. Wilforlide A without epoxide or 1,4-dipolar structure is inactive to all these signaling pathways, and only exhibits marginal potency against inflammation in RA rats ([@B129]). Optimized derivatives with reduced toxicity may be used for further translational development.

![Chemical structures of compounds isolated from *Tripterygium wilfordii* Hook F. Red color labeled moieties essential to maintain biological activities.](fphar-09-00104-g001){#F1}

Summary
=======

On the basis of the pharmacological activities of compounds isolated from THWF, especially triptolide and celastrol, we conclude that the systemic evaluation of the *in vivo* activities of these compounds is still needed. Targeted delivery systems, structure modifications, and the mechanisms of action of these compounds are essential in the design of novel derivatives with reduced cytotoxicity, improved efficacy, and increased therapeutic index.

Author Contributions
====================

S-RC, YtW, and YW mainly drafted the work critical for important intellectual content; YD, JZ, and LL finished the SAR discussion; all authors approved the version to be published.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was partially supported by Macao Science and Technology Development Fund 041/2014/A1, Research Fund of the University of Macau MYRG 2016-00105-ICMS-QRCM, and MYRG 2017-00116-ICMS-QRCM to YW, and MYRG2015-00098-ICMS-QRCM to YtW.

AMPK

:   AMP-activated protein kinase

ATP

:   adenosine triphosphate

BMP

:   bone morphogenetic protein

CDC

:   cell division cycle

CDK

:   cyclin dependent kinase

CYP

:   cytochrome protein

DEN

:   diethylnitrosamine

ER

:   endoplasmic reticulum

GCase

:   glucocerebrosidase

HCC

:   hepatocellular carcinoma

HSF

:   heat shock factor

HSP

:   heat shock protein

IFN

:   interferon

IL

:   interleukin

LPS

:   lipopolysaccharide

MDR

:   multi-drug resistance

mTOR

:   mammalian target of rapamycin

NF

:   nuclear factor

NLRP3

:   NLR family pyrin domain containing 3

NSCLC

:   non-small cell lung carcinoma

RA

:   rheumatoid arthritis

ROS

:   reactive oxygen species

RXRα

:   retinoid X receptor-α

SHIP

:   inositol polyphosphate-5-phosphatease

STAT

:   signal transducer and activator of transcription

TGF

:   transforming growth factor

TLR

:   toll-like receptor

TNF

:   tumor necrosis factor

Treg

:   T regulatory

TWHF

:   *Tripterygium wilfordii* Hook F

XBP1

:   X box binding protein 1
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